How Does Semaglutide Work? Mechanism of Action, Per the Research

Semaglutide is a prescription medicine, and every question about whether it is appropriate for a given person belongs with a licensed prescribing clinician. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. What follows is a summary of how the published pharmacology literature describes the molecule's mechanism of action, with a deliberate separation between mechanisms that are well established and those that remain proposed or under investigation.

The short answer from the pharmacology literature

Reviews of semaglutide describe it as a synthetic analogue of the incretin hormone glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor (GLP-1R), with structural modifications that extend its circulating half-life enough to support once-weekly administration, as described in a review of the discovery and development of liraglutide and semaglutide (PMID 31031702). A 2024 mechanism-focused review summarised the downstream consequences of that receptor activation as glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying and reduced appetite signalling (PMID 39728000). In other words, researchers describe semaglutide as working by imitating a gut hormone rather than by acting on a single organ.

What semaglutide binds: the GLP-1 receptor

Receptor class and signalling architecture

The GLP-1 receptor is a class B1 G-protein-coupled receptor, and a 2025 review of structural pharmacology described how peptide agonists engage its large extracellular domain and transmembrane core to stabilise active receptor conformations that couple primarily to Gs proteins (PMID 40221226). That same review discussed how different agonists can stabilise distinct receptor conformations, producing differences in G-protein coupling, β-arrestin recruitment and receptor internalisation — a phenomenon generally called biased agonism (PMID 40221226). This structural work is largely in-vitro and structural-biology based, and the authors framed it as a basis for understanding why peptides that hit the same receptor can behave differently in the body (PMID 40221226).

Gs coupling raises intracellular cyclic AMP and activates protein kinase A and the exchange protein directly activated by cAMP, and a 2024 review attributed the insulinotropic actions of GLP-1 receptor agonists in pancreatic beta cells to this cAMP-dependent cascade (PMID 39728000). A separate 2024 review of the molecular mechanisms of semaglutide and liraglutide in obesity similarly described GLP-1R activation as the common upstream event linking metabolic and appetite-related effects (PMID 38742021).

How the molecule was engineered for duration

Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. The development review reported that semaglutide incorporates an amino-acid substitution that reduces DPP-4 cleavage and a fatty di-acid side chain attached via a spacer, which promotes reversible binding to serum albumin and slows renal clearance (PMID 31031702). The authors described this acylation strategy as the key structural step that converted a short-lived hormone mimic into a once-weekly agent (PMID 31031702). A later review of semaglutide in obesity made the same point that the protracted pharmacokinetic profile underpins its weekly subcutaneous use (PMID 34942372).

Established peripheral mechanisms

Glucose-dependent insulin secretion

The incretin effect describes the amplification of insulin release when glucose arrives through the gut. The 2024 mechanism review reported that semaglutide enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning the stimulus diminishes as glucose falls (PMID 39728000). That glucose dependence is the reason reviews of GLP-1 receptor agonists have generally described a low intrinsic risk of hypoglycaemia when used without insulin secretagogues, as discussed in a safety review of semaglutide (PMID 34305810).

Glucagon suppression and hepatic glucose output

The same mechanism review described suppression of inappropriately elevated glucagon secretion from pancreatic alpha cells as a second pancreatic action, which researchers linked to reduced hepatic glucose production (PMID 39728000). A review of semaglutide for obesity summarised the combined pancreatic actions as the basis for its glucose-lowering profile in type 2 diabetes (PMID 34942372).

Gastric emptying and gut transit

A review of semaglutide as a weight-management medicine reported that delayed gastric emptying contributes to increased satiety and reduced energy intake (PMID 34706925). The 2024 obesity mechanism review described the same slowing of gastrointestinal transit as part of the integrated appetite-suppressing effect rather than as a standalone mechanism (PMID 38742021). Reviews have also connected this action to the gastrointestinal adverse events most commonly recorded in trials (PMID 34305810).

Central mechanisms: appetite circuits in animal work

The clearest mechanistic data on appetite come from preclinical work and should be read as such. A 2020 rodent study reported that semaglutide lowered body weight in rodents through distributed neural pathways, with the investigators mapping accessible brain regions and showing that the effect did not depend on a single hypothalamic or hindbrain nucleus (PMID 32213703). That study described direct access of the peptide to areas outside the blood-brain barrier and indirect engagement of secondary neuronal populations, and the researchers interpreted the weight reduction as arising from a network rather than one site (PMID 32213703). These were animal experiments, and the authors framed them as mechanistic rather than clinical evidence (PMID 32213703).

Human-facing reviews have summarised the same concept more generally, describing reduced appetite, altered food preference and lower energy intake as centrally mediated contributors to weight change with GLP-1 receptor agonists (PMID 38742021), and a weight-management review attributed the appetite effects of semaglutide to hypothalamic appetite-regulating centres (PMID 34706925).

What clinical trials measured downstream of the mechanism

Mechanism is inferred, in part, from what controlled trials recorded. In SUSTAIN 1, a double-blind phase 3a trial, researchers reported that once-weekly semaglutide 0.5 mg and 1.0 mg reduced HbA1c and body weight more than placebo over 30 weeks in people with type 2 diabetes (PMID 28110911). In SUSTAIN 7, an open-label phase 3b trial, the study compared once-weekly semaglutide with once-weekly dulaglutide over 40 weeks and reported greater reductions in HbA1c and body weight with semaglutide at the doses compared (PMID 29397376). A review of semaglutide for obesity described the 2.4 mg once-weekly formulation as the product developed for chronic weight management (PMID 34706925). These are trial findings, not instructions; decisions about product, dose and suitability rest with a prescribing clinician.

Established mechanism versus proposed mechanism

On the proposed side, a 2025 design paper described the evoke and evoke+ programme as two large-scale, double-blind, placebo-controlled phase 3 studies evaluating the efficacy, safety and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease, which the authors framed as a prospective test of a hypothesised neurological mechanism rather than an established one (PMID 39780249). A separate commentary reviewed ophthalmic observations associated with semaglutide and discussed how they should be interpreted alongside rapid glycaemic change (PMID 37122431).

Adverse Events: What Studies Report

A 2021 safety review of semaglutide reported that gastrointestinal events — nausea, vomiting, diarrhoea and constipation — were the most frequently recorded adverse events across the clinical programme, and the authors described them as generally mild to moderate and most common during dose escalation (PMID 34305810). In SUSTAIN 1, researchers reported nausea and diarrhoea among the most common adverse events with semaglutide compared with placebo (PMID 28110911). SUSTAIN 7 likewise reported gastrointestinal events as the most frequent adverse events in both the semaglutide and dulaglutide groups (PMID 29397376). The safety review also discussed areas of ongoing monitoring, including pancreatic, thyroid C-cell and retinal signals, and described the evidence for these as requiring continued surveillance (PMID 34305810). Mechanistically, the gastrointestinal profile is usually attributed to the same slowing of gastric emptying and central signalling that mediates satiety (PMID 39728000).

Regulatory and clinical framing

Semaglutide is a regulated prescription medicine. A 2022 review described the approval of a semaglutide product for chronic weight management in adults meeting specified criteria, alongside earlier approvals for type 2 diabetes (PMID 34706925), and a 2023 review summarised its place in obesity pharmacotherapy (PMID 34942372). Indications, contraindications, monitoring and product selection are matters for a licensed clinician and the approved labelling in the relevant jurisdiction.

Limits of what mechanism can tell you

Mechanistic understanding explains plausibility, not individual outcome. Structural pharmacology has characterised how the receptor is engaged (PMID 40221226), rodent work has mapped where in the brain the signal is read (PMID 32213703), and randomised trials have measured what happened to glycaemic and weight endpoints under controlled conditions (PMID 28110911, PMID 29397376). Translating those layers into an individual's care requires clinical assessment. PeptideU's broader semaglutide overview collects the trial literature in one place; it, like this page, is educational only.

References

• Structural pharmacology and mechanisms of GLP-1R signaling (Trends in Pharmacological Sciences, 2025)
• Spotlight on the Mechanism of Action of Semaglutide (Current Issues in Molecular Biology, 2024)
• Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity (Frontiers in Nutrition, 2024)
• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1) (The Lancet Diabetes & Endocrinology, 2017)
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) (The Lancet Diabetes & Endocrinology, 2018)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
• Semaglutide-eye-catching results (World Journal of Diabetes, 2023)
• evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease (Alzheimer's Research & Therapy, 2025)